Home page tells that "Mr Kempler was appointed as a Non-Executive Chairman of Opthea Limited, an ASX listed drug development company developing innovative, biologics-based therapies for the treatment of eye diseases, on November 30, 2015 ".
Opthea has developed a drug OPT 302 against "Wet (neovascular) age-related macular degeneration (wet AMD) and diabetic macular edema (DME) are the leading causes of visual impairment in the elderly and diabetic populations respectively. Now ATHE has listed also age-related macular degeneration as one of the potential new areas for ATH's drugs but not wet AMD but the dry AMD, I think. So there could one day be some kind of co-operation.
Have you seen the new home page ?, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $570 | 149.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 13513113 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130775819 | 29 |
View Market Depth
| Last trade - 15.46pm 27/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |